Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | serine/threonine protein kinase | 0.0049 | 0.2656 | 0.2655 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.2648 | 0.3024 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0049 | 0.2656 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0049 | 0.2648 | 0.997 |
Brugia malayi | MAP kinase sur-1 | 0.0049 | 0.2656 | 0.3033 |
Loa Loa (eye worm) | hypothetical protein | 0.0145 | 0.8756 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0049 | 0.2656 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0049 | 0.2656 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0049 | 0.2648 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0049 | 0.2648 | 0.997 |
Schistosoma mansoni | hypothetical protein | 0.0022 | 0.091 | 0.091 |
Loa Loa (eye worm) | type III restriction enzyme | 0.0008 | 0 | 0.0001 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0049 | 0.2656 | 1 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0049 | 0.2656 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0049 | 0.2656 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase | 0.0049 | 0.2656 | 0.2656 |
Echinococcus multilocularis | Ataxin 2, N terminal,domain containing protein | 0.0022 | 0.091 | 0.091 |
Brugia malayi | hypothetical protein | 0.0032 | 0.1531 | 0.1748 |
Entamoeba histolytica | DNA repair protein, putative | 0.0008 | 0 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.0049 | 0.2656 | 0.2656 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0049 | 0.2648 | 1 |
Echinococcus multilocularis | geminin | 0.0164 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0145 | 0.8756 | 1 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0049 | 0.2656 | 0.3033 |
Brugia malayi | hypothetical protein | 0.0049 | 0.2648 | 0.3024 |
Schistosoma mansoni | hypothetical protein | 0.0164 | 1 | 1 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0049 | 0.2656 | 1 |
Echinococcus granulosus | Ataxin 2 N terminaldomain containing protein | 0.0022 | 0.091 | 0.091 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0049 | 0.2656 | 1 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.0049 | 0.2656 | 0.2656 |
Leishmania major | hypothetical protein, conserved | 0.0049 | 0.2648 | 0.997 |
Echinococcus multilocularis | muscleblind protein | 0.0145 | 0.8756 | 0.8756 |
Loa Loa (eye worm) | hypothetical protein | 0.0008 | 0 | 0.0001 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0049 | 0.2648 | 0.997 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.0049 | 0.2656 | 0.2656 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0049 | 0.2656 | 1 |
Brugia malayi | Muscleblind-like protein | 0.0145 | 0.8756 | 1 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0049 | 0.2656 | 0.5 |
Entamoeba histolytica | DNA repair protein, putative | 0.0008 | 0 | 0.5 |
Echinococcus granulosus | muscleblind protein | 0.0145 | 0.8756 | 0.8756 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0049 | 0.2648 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0164 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0049 | 0.2656 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.0049 | 0.2656 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0008 | 0 | 0.0001 |
Echinococcus multilocularis | muscleblind protein 1 | 0.0145 | 0.8756 | 0.8756 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0049 | 0.2656 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0049 | 0.2656 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.